551. Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi®
- Author
-
Kyla Ramey, Katana Ashley Anne, Kato Darryl, Tran Chinh Viet, Cheng Y. Yang, Link John O, Debi Jin, Yujin Wang, Kobayashi Tetsuya, Karki Kapil Kumar, Armando G. Villaseñor, Todd C. Appleby, Kelly Wang, Sangi Michael, Jeff Zablocki, Randy Vivian, Brian E. Schultz, Yang Zheng-Yu, Guofeng Cheng, Dustin Siegel, Zipfel Sheila, Ona Barauskas, James G. Taylor, Martinez Ruben, Katie Chan, and Adam J. Schrier
- Subjects
Cyclopropanes ,Aminoisobutyric Acids ,Macrocyclic Compounds ,Proline ,Sofosbuvir ,Lactams, Macrocyclic ,Hepatitis C virus ,Voxilaprevir ,medicine.medical_treatment ,Clinical Biochemistry ,Pharmaceutical Science ,Hepacivirus ,Microbial Sensitivity Tests ,Viral Nonstructural Proteins ,medicine.disease_cause ,Antiviral Agents ,Heterocyclic Compounds, 4 or More Rings ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,Leucine ,Quinoxalines ,Drug Discovery ,Genotype ,medicine ,Humans ,Protease Inhibitors ,Protease inhibitor (pharmacology) ,Molecular Biology ,Sulfonamides ,NS3 ,Protease ,Dose-Response Relationship, Drug ,Molecular Structure ,biology ,010405 organic chemistry ,Chemistry ,Organic Chemistry ,Virology ,0104 chemical sciences ,Drug Combinations ,010404 medicinal & biomolecular chemistry ,Alanine transaminase ,biology.protein ,Molecular Medicine ,Carbamates ,medicine.drug - Abstract
Treatment of hepatitis C virus (HCV) infection has been historically challenging due the high viral genetic complexity wherein there are eight distinct genotypes and at least 86 viral subtypes. While HCV NS3/4A protease inhibitors are an established treatment option for genotype 1 infection, limited coverage of genotypes 2 and/or 3 combined with serum alanine transaminase (ALT) elevations for some compounds has limited the broad utility of this therapeutic class. Our discovery efforts were focused on identifying an NS3/4A protease inhibitor with pan-genotypic antiviral activity, improved coverage of resistance associated substitutions, and a decreased risk of hepatotoxicity. Towards this goal, distinct interactions with the conserved catalytic triad of the NS3/4A protease were identified that improved genotype 3 antiviral activity. We further discovered that protein adduct formation strongly correlated with clinical ALT elevation for this therapeutic class. Improving metabolic stability and decreasing protein adduct formation through structural modifications ultimately resulted in voxilaprevir. Voxilaprevir, in combination with sofosbuvir and velpatasvir, has demonstrated pan-genotypic antiviral clinical activity. Furthermore, hepatotoxicity was not observed in Phase 3 clinical trials with voxilaprevir, consistent with our design strategy. Vosevi® (sofosbuvir, velpatasvir, and voxilaprevir) is now an approved pan-genotypic treatment option for the most difficult-to-cure individuals who have previously failed direct acting antiviral therapy.
- Published
- 2019
- Full Text
- View/download PDF